





Express Mail No.: EL 500 575 431 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: John C. Reed

Application No.: 09/724,425

Filed: November 28, 2000

REGULATION OF BCL-2 GENE For:

EXPRESSION

Group Art Unit: 1635

Examiner: M. Schmidt

Attorney Docket No.: 10412-026

FEE TRANSMITTAL SHEET

Assistant Commissioner for Patents Box AF Washington, D.C. 20231

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$252.

The claim amendment fee has been estimated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)	SMALL ENTITY				OTHER THAN A SMALL ENTITY		
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE		ADDIT. FEE	OR	RATE		ADDIT. FEE
TOTAL	33	MINUS	41		0	× 9	\$			× 18	\$	0.00
INDEP.	10	MINUS	7	=_	3	× 42	\$_			× 84	\$	252.00
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM						140	\$			280	\$	
U FIRST FI	RESENTATION OF M	OLIN EL DE				TOTAL	\$		OR	TOTAL	\$	252.00

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted

Laura A. Coruzzi

PENNIE & EDMONDS LLP 1155 Avenue of Americas New York, N.Y. 10036-2711

(212) 790-9090

Enclosure

Date August 8, 2002





出版 THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: John C. Reed

Serial No.: 09/724,425

Examiner: Schmidt, M. Filed: November 28, 2000

REGULATION OF BCL-2 GENE For:

EXPRESSION

Attorney Docket No.: 10412-026

Group Art Unit: 1635

AMENDMENT UNDER 37 C.F.R. §1.116

Assistant Commissioner for Patents

Box AF

Washington, D.C. 20231

Sir:

In response to the Final Office Action dated February 8, 2002, please enter the following amendments and consider the following remarks intended to put all the claims into form for allowance. Applicants also submit herewith in connection with the instant application: (1) a Petition for Extension of Time under 37 C.F.R. § 1.136(a) for three months from May 8, 2002, to and including August 8, 2002; (2) a Notice of Appeal, accompanied by the appropriate fee; (3) an Amendment fee transmittal sheet; (4) claims as pending upon entry of the amendments made herein, attached hereto as Exhibit A; (5) a copy of Scher et al., 2000, Proc. ASCO, 19:199a (abstract 774), attached hereto as Exhibit B; (6) a copy of Tolcher et al., 2000, Clin. Cancer Res Supp, 6:4571s (abstract 527), attached hereto as Exhibit C; (7) a copy of Marcucci et al., 2000, J Amer Soc Hematology, Blood Supp, 96(11):119a (abstract 513), attached hereto as Exhibit D; and (8) a copy of Jansen et al., 2000. Lancet, 356:1728-32, attached hereto as Exhibit E.

08/12/2002 AMONDAF1 00000088 161150 09724425

01 FC:102

252.00 CH